DNL-593
- Generic Name
- DNL-593
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Denali Therapeutics Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT05262023
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇧🇪University of Antwerp, Antwerp, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath